Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Breast 2Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1

Interventions

Cisplatin 27Magnetic Resonance Spectroscopy 23pembrolizumab 22Specimen Handling 19Cetuximab 17Nivolumab 14Carboplatin 13Platinum 111,2-diaminocyclohexaneplatinum II citrate 11Radiotherapy, Intensity-Modulated 10Radiotherapy 9Radiation 9Paclitaxel 8Docetaxel 8Biopsy 8Surveys and Questionnaires 6Immunoglobulin G 6Disulfides 6atezolizumab 5Ipilimumab 5Fluorouracil 5dostarlimab 4cemiplimab 4Gemcitabine 4CTLA-4 Antigen 4(225)Ac-DOTA-c(RGDyK) 4toripalimab 3relatlimab 3fludarabine 3cabozantinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Alpelisib × Head & Neck × 30 days × Clear all
NCT04997902 2026-06-05

Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

Kura Oncology, Inc.

Phase 1/2 Completed
45 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡